| docetaxel / Generic mfg. |
NCT00006038: Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer |
|
|
| Completed | 2 | | US | cisplatin, docetaxel, floxuridine, fluorouracil, leucovorin calcium, conventional surgery | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 02/03 | 02/03 | | |
SAKK 75/02, NCT00072033: Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer |
|
|
| Completed | 2 | 66 | Europe | Cisplatin and Docetaxel | Swiss Group for Clinical Cancer Research | Esophageal Cancer | 03/03 | 05/10 | | |
NCT00003864: Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus |
|
|
| Completed | 2 | | US, RoW | carboplatin, docetaxel | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer | 01/04 | | | |
NCT00004235: Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach |
|
|
| Completed | 2 | 47 | US, Canada | docetaxel, irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 08/04 | 08/04 | | |
NCT00165464: Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer |
|
|
| Completed | 2 | 54 | US | Taxotere, Cisplatin, Irinotecan | Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Aventis Pharmaceuticals | Esophageal Cancer, Gastric Cancer, GE Junction Cancer | 03/05 | 04/09 | | |
NCT00318903: Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer |
|
|
| Completed | 2 | 25 | US | Irinotecan (drug), Camptosar, Taxotere (drug), Docetaxel, Radiotherapy (procedure), Esophagectomy (procedure) | University of Alabama at Birmingham, Aventis Pharmaceuticals, Pharmacia and Upjohn | Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus | | 04/06 | | |
NCT00137813: Avastin and Taxotere for Esophagogastric Cancer |
|
|
| Completed | 2 | 42 | US | Docetaxel, AvaTax, Bevacizumab | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Genentech, Inc., Sanofi | Esophageal Cancer, Gastric Cancer | 09/06 | 09/09 | | |
NCT00054457: Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction |
|
|
| Completed | 2 | 46 | US | capecitabine, docetaxel | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 02/07 | 02/08 | | |
NCT00216008: Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation. |
|
|
| Terminated | 2 | 42 | US | docetaxel, cisplatin, radiation, surgery | H. Lee Moffitt Cancer Center and Research Institute, Aventis Pharmaceuticals | Esophageal Adenocarcinomas, Adenocarcinomas of the Gastroesophageal Junction | 02/07 | 02/07 | | |
SAKK 76/02, NCT00238407: Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 21 | Europe | Docetaxel and Cisplatin, Radiotherapy | Swiss Group for Clinical Cancer Research | Esophageal Cancer | 02/08 | 08/10 | | |
NCT00253370: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 44 | US | BAY 43-9006, Sorafenib (NSC724772), BAY 54-9085 (tosylate salt), docetaxel, Taxotere, RP 56976, NSC #628503, cisplatin, Cis-diaminedichloroplatinum, Cis-diaminedichloroplatinum (II), diaminedichloroplatinum, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875. | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer | 05/08 | 09/10 | | |
NCT00394433: Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer |
|
|
| Completed | 2 | 38 | US | Bevacizumab, Avastin, Docetaxel, Taxotere, Docefrez, Cisplatin, Platinol-AQ, Platinol, Irinotecan, Camptosar | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc. | Esophageal Cancer, Stomach Cancer | 11/08 | 10/16 | | |
NCT00177255: A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers |
|
|
| Terminated | 2 | 40 | US | Docetaxel, Capecitabine, Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14)., Each cycle will consist of 21 days., Cycle 2 will begin on day 22. | University of Pittsburgh, Aventis Pharmaceuticals, Roche Pharma AG | Cancer | 12/08 | 12/08 | | |
NCT00737373 / 2006-006936-24: Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer |
|
|
| Completed | 2 | 143 | Europe | Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid | Krankenhaus Nordwest | Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | 12/09 | 03/11 | | |
NCT01640860: Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal Cancer |
|
|
| Completed | 2 | 36 | RoW | | Chonnam National University Hospital, Sanofi | Esophageal Cancer | 12/09 | 12/11 | | |
NCT00448760: Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery |
|
|
| Completed | 2 | 29 | US | Docetaxel, Taxotere, Floxuridine, FUdR, Leucovorin, Oxaliplatin, Microarray analysis, reverse transcriptase-polymerase chain reaction, Conventional surgery | University of Miami | Esophageal Cancer | 04/10 | 04/10 | | |
NCT00551759: Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer |
|
|
| Terminated | 2 | 22 | US | 5-Fluorouracil, 5-FU, Fluorouracil, Adrucil, Efudex, Oxaliplatin, Trans-l-diaminocyclohexane oxalatoplatinum, Cis-[oxalato (trans-I-1,2-diaminocyclohexane) platinum(II)], l-OHP, Eloxatin, Eloxatine, Dacplat, 5R96669, Cetuximab, Erbitux, C225, Docetaxel, Taxotere, RP 56976, Surgery, Radiotherapy | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer | 10/11 | 02/14 | | |
NCT00757172: Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction |
|
|
| Completed | 2 | 70 | US | panitumumab, cisplatin, docetaxel, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Amgen | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | 11/11 | 12/14 | | |
|
|
|
NCT00390416: Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma |
|
|
| Completed | 2 | 48 | US | Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin | Memorial Sloan Kettering Cancer Center, Sanofi, Genentech, Inc. | Stomach Neoplasms, Esophageal Neoplasms | 01/12 | 01/12 | | |
FLOT3, NCT00849615: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction |
|
|
| Completed | 2 | 252 | Europe | Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid | Krankenhaus Nordwest | Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | 01/12 | 01/16 | | |
NCT00824811: Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel |
|
|
| Withdrawn | 2 | 0 | US | Cyclosporine Eye Drops (Restasis), Cyclosporine eyedrops, Cyclosporine Opthalmic Emulsion 0.05%, Lubricant Eye Drops (Refresh Endura™), Refresh Endura™ eye drops, Fluorometholone Eye Drops (FML Forte®), Fluorometholone 0.25% Opthalmic Suspension | M.D. Anderson Cancer Center, Allergan | Epiphora | | | | |
NCT01129206: Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy |
|
|
| Completed | 2 | 6 | US | pralatrexate, FOLOTYN, PDX, docetaxel, RP 56976, Taxotere, TXT, fludeoxyglucose F 18, 18FDG, FDG, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, fluorodeoxyglucose F 18, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed | Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, Spectrum Pharmaceuticals, Inc | Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer | 09/12 | | | |
NCT00217581: Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 39 | US | Bevacizumab, Avastin, Docetaxel, Taxotere, Oxaliplatin, Eloxatin | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 11/12 | 01/13 | | |
NCT00733889 / 2006-001880-42: A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma |
|
|
| Completed | 2 | 50 | Europe | cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC, Sanofi | Esophageal Carcinoma | 11/12 | 11/12 | | |
NCT01710592 / 2006-003332-29: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer |
|
|
| Completed | 2 | 35 | Europe | Epirubicin, Oxaliplatin, Capecitabine, Docetaxel | Cancer Trials Ireland | Gastro Oesophageal Cancer | 12/12 | | | |
| Terminated | 2 | 50 | Europe | 5-FU, Cisplatin, Taxotere, Docetaxel, Cetuximab, Erbitux, Radiation during chemoradio-immunotherapy | Arbeitsgemeinschaft medikamentoese Tumortherapie, Merck Sharp & Dohme LLC, Sanofi | Esophageal Cancer | 12/12 | 12/12 | | |
NCT00938470: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Completed | 2 | 73 | US | capecitabine, docetaxel, fluorouracil, oxaliplatin, radiation therapy, therapeutic conventional surgery | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer | 12/13 | 03/18 | | |
NCT01469598: Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer |
|
|
| Completed | 2 | 24 | RoW | Gemcitabine/Docetaxel | Samsung Medical Center | Metastatic Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma | 02/14 | 01/15 | | |
| Completed | 2 | 53 | Europe | 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy | AIO-Studien-gGmbH, Roche Pharma AG | Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach | 08/14 | 09/16 | | |
|
NCT00183872: Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Completed | 2 | 40 | US | irinotecan, docetaxel | University of Southern California, Sanofi | Gastric Cancer, Esophageal Neoplasms | 10/14 | 10/15 | | |
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma |
|
|
| Completed | 2 | 22 | US | epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery. | Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University | Esophageal Cancer, Gastric Cancer | 02/15 | 02/15 | | |
|
NCT01715233: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. |
|
|
| Completed | 2 | 27 | US | Docetaxel, Modified DCF, Leucovorin, Fluorouracil, FU, Cisplatin, Carboplatin | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer | 06/15 | 04/17 | | |
NCT01932580: Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma |
|
|
| Completed | 2 | 10 | Canada | FLOT (5-fluorouracil, oxaliplatin, docetaxel), Oxaliplatin: Eloxatin, Docetaxel: Taxotere | McGill University | Gastric Adenocarcinoma, Esophageal Adenocarcinoma | 06/15 | 06/15 | | |
NCT01608464: Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer |
|
|
| Terminated | 2 | 170 | RoW | irinotecan and docetaxel, Irinotecan, Docetaxel, Cisplatin, fluorouracil and concurrent radiation therapy, Cisplatin, 5-FU, Concurrent RT with CDDP and 5-FU | King Faisal Specialist Hospital & Research Center | Carcinoma of Esophagus | 09/15 | 09/15 | | |
| Terminated | 2 | 105 | Europe | FU-CDDP, Fluoro-uracil+CisPlatin, LV5FU2-CDDP, Elvorin+Fluoro-uracil+CisPlatin, FOLFOX, Oxaliplatin+Fluoro-uracil+Elvorin, TPF, Docetaxel+CisPlatine+Fluoro-uracile, Best Supportive Care, antalgic treatment, nutritional support, ... | Centre Oscar Lambret, National Cancer Institute, France | Squamous Cell Carcinoma of Esophagus | 01/16 | 01/17 | | |
NCT00003103: Chemotherapy in Treating Patients With Solid Tumors |
|
|
| Completed | 1/2 | 57 | US | oblimersen sodium, docetaxel | Memorial Sloan Kettering Cancer Center | Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 08/02 | 08/02 | | |
SAKK 75/06, NCT00445861: Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery |
|
|
| Completed | 1/2 | 27 | Europe | cetuximab + docetaxel + cisplatin, Treatment level 1, Treatment level 2, conventional surgery | Swiss Group for Clinical Cancer Research | Esophageal Cancer | 11/08 | 11/08 | | |
NCT00209716: Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer. |
|
|
| Completed | 1/2 | 30 | Japan | Taxotere, Docetaxel, 5-Fluorouracil, fluorouracil, Briplatin, Cisplatin | Hokkaido Gastrointestinal Cancer Study Group, Hokkaido University Hospital | Esophageal Cancer | 10/09 | 11/09 | | |
NCT00209690: Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer. |
|
|
| Completed | 1/2 | 30 | Japan | Taxotere, Docetaxel, 5-FU, 5-Fluorouracil, Briplatin, Cisplatin,CDDP | Hokkaido Gastrointestinal Cancer Study Group, Hokkaido University Hospital | Esophageal Cancer | 12/09 | 04/10 | | |
NCT00732745: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Terminated | 1/2 | 9 | US | docetaxel, oxaliplatin, vandetanib, placebo | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | 06/10 | | | |
|
NCT00374985: Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction |
|
|
| Completed | 1/2 | 25 | Europe | Docetaxel, Oxaliplatin, Radiotherapy | Johannes Gutenberg University Mainz | Esophageal Neoplasms, Stomach Neoplasms | 09/13 | 09/13 | | |
